Metagenomi Therapeutics Research and Development Expenses 2022-2026 | MGX
Metagenomi Therapeutics research and development expenses from 2022 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
|
Metagenomi Therapeutics Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | $94 |
| 2024 | $109 |
| 2023 | $94 |
| 2022 | $43 |
| 2021 | $14 |
|
Metagenomi Therapeutics Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $19 |
| 2025-12-31 | $22 |
| 2025-09-30 | $25 |
| 2025-06-30 | $23 |
| 2025-03-31 | $25 |
| 2024-12-31 | $23 |
| 2024-09-30 | $26 |
| 2024-06-30 | $28 |
| 2024-03-31 | $31 |
| 2023-12-31 | $25 |
| 2023-09-30 | $27 |
| 2023-06-30 | $23 |
| 2023-03-31 | $20 |
| 2022-12-31 | |
| 2021-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.052B | $0.025B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |